TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00856401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH1-84 in parent study
Description: daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
Study: NCT02653521

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose adaptation
Description: Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
Study: NCT04001829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05133557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum containing xylitol and blackberry extract (BBE)
Description: On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chewing gum containing xylitol and blackberry extract (BBE)
Description: On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
Study: NCT04495374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
Study: NCT01791127

Intervention type: DEVICE
Intervention: market-released BIOTRONIK pacemaker system including one or two Siello S leads.
Study: NCT02190383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training
Description: awareness training, competing response training
Study: NCT02540473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized Therapy
Description: Relational psychotherapy mothers

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: one hour of free time to do with as they wish
Study: NCT02952794

Intervention type: PROCEDURE
Intervention: endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer

Intervention type: PROCEDURE
Intervention: endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer
Study: NCT03733184

Intervention type: PROCEDURE
Intervention: Cytoreduction and Heated Intraperitoneal Surgery
Description: Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).

Intervention type: PROCEDURE
Intervention: Cytoreduction and Heated Intraperitoneal Surgery
Description: Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
Study: NCT04495374

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group P0 will receive a placebo tablet, 02h before the surgical procedure
Study: NCT00353704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: capsule 150 mg x 1 per orally one hour before surgery
Study: NCT02056574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04662684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: No intervention
Study: NCT01416207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: 4 weekly injections of Avonex (IM)
Study: NCT01845701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine
Description: Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinine-Piperaquine
Description: It is a bisquinoline antimalarial drug (1,3-bis\[1-(7-chloro-4 quinolyl)-4- piperazinyl\]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
Study: NCT00353704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of saccharose (placebo) was administered about one hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine
Description: All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
Study: NCT02393495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine device TCu 380A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine device TCu 380A
Study: NCT01845701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Description: CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
Study: NCT02593734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: oral antipsychotic drug therapy
Study: NCT03205878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Patients will receive CPAP according to standard care
Study: NCT03973736

Intervention type: OTHER
Intervention: application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)
Description: Since the introduction of the new protocol in 2012, a single central multidisciplinary team has been formalized, with weekly discussion of cases, including different specialists from all the provincial hospitals. CT scans of discussed cases are reviewed by one of two experienced radiologists based on pre-defined criteria.
Study: NCT02593734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: oral antipsychotic drug therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amitryptaline
Description: oral antidepressant drug therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: oral drug therapy for depression
Study: NCT01624155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: EMR referral to teratogen and contraception counseling
Study: NCT02822807

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Study: NCT01380860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colostomy with mesh implantation
Description: Colostomy with mesh implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple colostomy
Description: Colostomy with no mesh implantation.
Study: NCT03115060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
Description: intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
Description: intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
Description: intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
Study: NCT01714414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT
Study: NCT00961597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meniscus repair for red/white tears without PRP
Description: Same operation as experimental, only without the use of platelet rich plasma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscus repair with PRP
Description: Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
Study: NCT03741283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimisation of nutrition and medication
Description: 1. Inter-professional optimisation of medication prescribing:~   Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~2. Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~* Dysphagia: occupational therapy intervention.~* Oral cavity problems: odontological intervention.~* Depression: geriatric intervention.~* Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention.
Study: NCT01388088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 25 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: 5 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day
Study: NCT02143089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley's Catheter
Description: Urinary tract infection inpatient catheterized versus non catheterized
Study: NCT02052349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Dose of ABT-333
Study: NCT01780688

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarettes (CC)
Description: Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional cigarettes (CC)
Description: Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.1
Description: Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.1
Description: Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
Study: NCT03775278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-303
Description: Investigational drug
Study: NCT02672774

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnification endoscopy with narrow band imaging
Description: Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnification endoscopy with narrow band imaging
Description: Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.

Intervention type: DEVICE
Group type: OTHER
Intervention: Probe based confocal laser endomicroscopy
Description: Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.

Intervention type: DEVICE
Group type: OTHER
Intervention: Probe based confocal laser endomicroscopy
Description: Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
Study: NCT00783562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension-oriented exercise program
Description: The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
Study: NCT04119284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior body tether (ABT)
Description: To insert the ABT in patients to correct AIS.
Study: NCT03775278

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03523533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiocatheter
Description: Placement of angiocatheter in internal jugular vein
Study: NCT01303627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: 1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
Study: NCT01343082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-111 ophthalmic solution
Study: NCT03851653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Cognitive-behavioural intervention for weight loss and lifestyle change
Study: NCT03876067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cardioplegic Solutions
Description: in which in which only cold blood cardioplegia
Study: NCT00873795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole , sertraline
Description: In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aripiprazole , sertraline
Description: In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
Study: NCT00855517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Study: NCT02221934

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Altius
Description: Electrical signal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Altius
Description: Electrical signal
Study: NCT01258114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPA treatment (ST)
Description: Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~* nutritional counseling (french nutritional recommendations booklet) ;~* caloric restriction and physical training on demand (non mandatory).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non SPA treatment (NST)
Description: Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)
Study: NCT00618475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: 10 sessions~1 hour per week
Study: NCT00783562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative Brochure
Description: The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative Brochure
Description: The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
Study: NCT03862937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exercise training + whey protein
Description: Whey protein (2x / day - 20g for breakfast and 20g for dinner).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training + placebo (maltodextrin)
Description: Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
Study: NCT04567173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 convalescent plasma
Description: convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
Study: NCT01887379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRDF furosemide
Description: The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRDF furosemide
Description: The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
Study: NCT03180346

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO
Description: Single Use Negative Pressure Dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel
Description: Occlusive surgical dressing infused with ionized silver